Animal | Compound | Dose (mg/kg) | n | Mean voided volume (ml) | Voiding frequency | Total voided volume (ml) |
---|---|---|---|---|---|---|
Normal | Vehicle | 6 | 1.10 ± 0.12 | 3.3 ± 0.4 | 3.49 ± 0.30 | |
Cerebral infarction | Vehicle | 7 | 0.45 ± 0.04## | 8.3 ± 0.6## | 3.66 ± 0.33 | |
KPR-5714 | 0.3 | 6 | 0.62 ± 0.13 | 6.8 ± 0.6 | 3.89 ± 0.43 | |
1 | 5 | 0.70 ± 0.05* | 5.4 ± 0.5** | 3.67 ± 0.14 | ||
Cerebral infarction | Vehicle | 6 | 0.41 ± 0.02## | 8.5 ± 0.4## | 3.45 ± 0.19 | |
Tolterodine tartrate | 3 | 7 | 0.57 ± 0.15 | 7.9 ± 1.2 | 3.53 ± 0.34 | |
10 | 9 | 0.53 ± 0.07 | 7.2 ± 0.8 | 3.37 ± 0.13 | ||
Mirabegron | 3 | 7 | 0.56 ± 0.08* | 6.7 ± 0.8 | 3.45 ± 0.24 | |
10 | 7 | 0.61 ± 0.05* | 6.1 ± 0.7 | 3.60 ± 0.24 |
aP < 0.01 vs. vehicle-treated normal rats.
bP < 0.05.
cP < 0.01 vs. vehicle-treated cerebral infarcted rats.